Financial News

TGV-inhalonix’s New Drug To Help Patients With Resistant Fungal Lung Infections

News Source: WiredPRNews.com
New York, New York, USA, 05/11/2017 /SubmitPressRelease123/


TGV-inhalonix, a New York drug development company behind ground-breaking Mul-1867 which gives hope to treating life-threatening, antibiotic-resistant bacterial lung infections in patients suffering from cystic fibrosis, announced that Mul-1867 has shown tremendous potential against clinical isolates of fungi from patients with cystic fibrosis and other severe lung infections.



The findings were published in Europe’s leading discovery journal -  International Journal of Antimicrobial Agents - and will be presented at the upcoming ASM - 2017 conference in June.

News Source: http://www.WiredPRNews.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback